|
|||||
|
|

Hospital management company Universal Health Services (NYSE:UHS) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 9.6% year on year to $4.28 billion. The company expects the full year’s revenue to be around $17.2 billion, close to analysts’ estimates. Its non-GAAP profit of $5.35 per share was 8.4% above analysts’ consensus estimates.
Is now the time to buy UHS? Find out in our full research report (it’s free).
Universal Health Services delivered a quarter that surpassed Wall Street’s expectations, with notable contributions from its acute care segment and improving expense control. Management highlighted that solid acute care revenues, aided by a 2% rise in adjusted admissions and effective cost management, drove a 10% increase in same-facility EBITDA. CEO Marc Miller acknowledged, "demand, especially for emergency services, has been very encouraging" at newly opened West Henderson Hospital, while the behavioral health segment continued to benefit from pricing gains despite modest volume growth.
Looking forward, Universal Health Services’ guidance is shaped by anticipated benefits from Medicaid supplemental payments and the ramp-up of newly opened and upcoming facilities, though management was clear about headwinds from policy changes. CFO Steve Filton cautioned that upcoming Medicaid reforms could reduce future supplemental payments, but emphasized, "we have great confidence in our ability to shift and be flexible, especially with several years of notice." The company is also prioritizing expansion of its outpatient behavioral health footprint to capture market share as payer trends shift.
Management attributed Q2 results to acute care growth, behavioral pricing strength, and disciplined cost control, while outlining proactive strategies to address both policy risks and operational challenges.
Universal Health Services expects Medicaid policy changes, continued outpatient expansion, and new facility ramp-up to shape revenue and margin trends in the coming quarters.
In the coming quarters, our analysts will focus on (1) the pace of outpatient behavioral health expansion and its impact on segment volumes, (2) the operational ramp of new facilities such as Cedar Hill and West Henderson, and (3) state-level developments regarding Medicaid supplemental payments and the One Beautiful Bill Act. Execution on technology initiatives and labor cost containment will also serve as important markers of progress.
Universal Health Services currently trades at $175.78, up from $154.99 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| 9 hours | |
| Nov-04 | |
| Nov-04 | |
| Nov-04 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Oct-30 | |
| Oct-30 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite